Filing Flows › Comparisons › ARVN vs SLN
Arvinas vs Silence Therapeutics: ARVN and SLN compared
Arvinas is the larger company: $500K of revenue in its latest quarter (Q3 2026) against $422K for Silence Therapeutics (Q1 2026). Silence Therapeutics is growing faster (+197% against -99% a year earlier).
Where the money goes: ARVN and SLN
Arvinas (ARVN) · Q3 2026
Arvinas, Q3 2026: revenue $500K (-99% year over year), net loss $53.9M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
Silence Therapeutics (SLN) · Q1 2026
Silence Therapeutics, Q1 2026: revenue $422K (+197% year over year), net loss $15.0M, operating cash flow −$15.6M. The chart follows the revenue to costs, profit and cash.
| Arvinas (ARVN) | Silence Therapeutics (SLN) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q1 2026 |
| Revenue | $500K | $422K |
| Revenue growth, Y/Y | -99% | +197% |
| Operating margin | n/m | n/m |
| Net earnings | −$53.9M | −$15.0M |
| Operating cash flow | −$10.4M | −$15.6M |
Questions
Which is bigger, Arvinas or Silence Therapeutics?
Arvinas is the larger company: $500K of revenue in its latest quarter (Q3 2026) against $422K for Silence Therapeutics (Q1 2026).
Is Arvinas or Silence Therapeutics growing faster?
Silence Therapeutics is growing faster (+197% against -99% a year earlier).
More: Arvinas earnings · how Arvinas makes money · Silence Therapeutics earnings · how Silence Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed May 7, 2026). Fiscal quarters can end on different dates. Not investment advice.